Related Experiment Videos
A two-step timed sequential treatment for acute myelocytic leukemia.
R B Geller1, P J Burke, J E Karp
1Adult Leukemia Program, Johns Hopkins Oncology Center, Baltimore.
Blood
|October 1, 1989
Summary
Intensive chemotherapy regimens improved complete remission rates for acute myelocytic leukemia (AML) patients. Younger patients (<55) with de novo AML experienced significantly longer disease-free survival and overall survival.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Adults with acute myelocytic leukemia (AML) have historically faced challenging treatment outcomes.
- Intensive timed sequential chemotherapy has been explored to improve remission and survival rates.
Purpose of the Study:
- To evaluate the efficacy of two intensive timed sequential chemotherapy regimens in adults with AML.
- To compare outcomes between de novo AML and secondary AML (SAML) or AML with a history of a hematologic disorder (AHD).
Main Methods:
- Two sequential clinical studies involving adults aged 16-80 with AML, including SAML and AHD.
- Study 1: High-dose cytarabine (ara-C) and daunorubicin (DRN) (Ac2-D-Ac).
- Study 2: Amsacrine followed by intensive cytarabine and daunorubicin (Ac2-D-Amsa, Ac6-D-Ac) to reduce toxicity.
Main Results:
- The first regimen (Ac2-D-Ac) achieved a 55% complete remission (CR) rate.
- The second regimen (Ac2-D-Amsa, Ac6-D-Ac) improved CR rates to 76% (de novo AML) and 54% (SAML-AHD).
- Younger patients (≤55) with de novo AML showed superior disease-free survival (DFS) and overall survival (OS) (median 17 and 18 months, respectively).
Conclusions:
- The modified intensive timed sequential therapy demonstrated improved CR rates in AML.
- Age is a critical prognostic factor for survival in AML patients.
- SAML-AHD patients exhibit refractoriness to aggressive chemotherapy, necessitating further research.